Sugi Predict

Sugi Predict / Targets / GABRR1

GABRR1

Gamma-aminobutyric acid receptor subunit rho-1 · P24046 · GABRR1 on Sugi Atlas →

33,913 patent compounds predicted against GABRR1, 14,744 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL65025 SCHEMBL65025 0.59 5/20
SCHEMBL339332 SCHEMBL339332 0.59 5/20
SCHEMBL352246 SCHEMBL352246 0.59 5/20
SCHEMBL377179 SCHEMBL377179 0.58 5/20
Acetic Acid Acetic Acid (SCHEMBL180921) 0.57 5/20
SCHEMBL268811 SCHEMBL268811 0.56 5/20
SCHEMBL21708 SCHEMBL21708 0.53 5/20
SCHEMBL66017 SCHEMBL66017 0.53 5/20
SCHEMBL28799 SCHEMBL28799 0.52 5/20
SCHEMBL22039 SCHEMBL22039 0.50 5/20
SCHEMBL109579 SCHEMBL109579 0.50 5/20
Icofungipen Icofungipen (SCHEMBL117349) 0.48 5/20
SCHEMBL268091 SCHEMBL268091 0.48 5/20
SCHEMBL338158 SCHEMBL338158 0.48 5/20
SCHEMBL168962 SCHEMBL168962 0.46 5/20
SCHEMBL250305 SCHEMBL250305 0.40 5/20
Tranexamic Acid Tranexamic Acid (SCHEMBL16974) 0.39 5/20
Tranexamic Acid Tranexamic Acid (SCHEMBL186034) 0.39 5/20
Tranexamic Acid Tranexamic Acid (SCHEMBL322487) 0.39 5/20
Tranexamic Acid Tranexamic Acid (SCHEMBL349408) 0.39 5/20

Clinical trials — most relevant to GABRR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Computational Assessment of GABA Receptor Modulation in PTSD PHASE4RECRUITING
Safety of Ramelteon in Elderly Subjects PHASE4COMPLETED
The Effects of Levetiracetam on Alcohol Dependent Subjects PHASE4COMPLETED
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia PHASE3COMPLETED
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia PHASE2COMPLETED
Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia PHASE2COMPLETED
Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome PHASE2RECRUITING
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Diazepam Trial in GAD65 Associated Epilepsy PHASE1/PHASE2WITHDRAWN
Neurosteroids and Acute Alcohol Intoxication in Humans PHASE1UNKNOWN
MEG Study of Acute STX209 Effects in ASD EARLY_PHASE1COMPLETED
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression EARLY_PHASE1RECRUITING
Pilot Study Evaluating Neuro-Imaging Correlates of Epigenetic Finding in Prediction of Chronic Postsurgical Pain nanUNKNOWN
GABA Biomarkers in Dravet Syndrome nanRECRUITING
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory nanCOMPLETED
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle nanCOMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain nanRECRUITING
A Positional Cloning Study on Schizophrenia nanCOMPLETED
Acute Intermittent Hypoxia in Traumatic Brain Injury nanCOMPLETED
GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA) nanCOMPLETED
Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk nanCOMPLETED
Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms nanCOMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Pharmacogenetics of Alcohol: Treatment Implications nanCOMPLETED
L-arginine add-on Therapy in Patients With Schizophrenia nanCOMPLETED
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GABRR1 binder may also engage these)

ProteinNameSimilarity
P50572 — 1.000 P50572 →
P56475 — 1.000 P56475 →
P56476 — 1.000 P56476 →
P47742 — 1.000 P47742 →
Q0II76 — 0.999 Q0II76 →
GABRR2 Gamma-aminobutyric acid receptor subunit rho-2 0.994 landscape →
P50573 — 0.991 P50573 →
GABRR3 Gamma-aminobutyric acid receptor subunit rho- 0.983 landscape →
Q08832 — 0.959 Q08832 →
P02713 — 0.959 P02713 →
P20782 — 0.951 P20782 →
P09660 — 0.950 P09660 →
P02715 — 0.949 P02715 →
P20237 — 0.948 P20237 →
P28471 — 0.948 P28471 →
Q708S4 — 0.948 Q708S4 →
P25109 — 0.948 P25109 →
CHRNE Acetylcholine receptor subunit epsilon 0.947 landscape →
P04758 — 0.947 P04758 →
GABRA4 Gamma-aminobutyric acid receptor subunit alpha-4 0.947 landscape →
Q9PTS8 — 0.945 Q9PTS8 →
Q9D6F4 — 0.945 Q9D6F4 →
Q68RJ7 — 0.943 Q68RJ7 →
P23979 — 0.943 P23979 →
P09690 — 0.940 P09690 →
P24045 — 0.939 P24045 →
HTR3A 5-hydroxytryptamine receptor 3A 0.939 landscape →
CHRNB1 Acetylcholine receptor subunit beta 0.938 landscape →
P35563 — 0.938 P35563 →
P04760 — 0.937 P04760 →